Literature DB >> 25806215

ZEPHYR: failure of a "spring wind" in lung cancer.

Alessandro Morabito1.   

Abstract

Entities:  

Year:  2013        PMID： 25806215      PMCID： PMC4367639          DOI： 10.3978/j.issn.2218-6751.2012.10.10

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  15 in total

Review 1.  Methodology of clinical trials with new molecular-targeted agents: where do we stand?

Authors:  A Morabito; M Di Maio; E De Maio; N Normanno; F Perrone
Journal:  Ann Oncol       Date:  2006-06       Impact factor: 32.976

Review 2.  Methodological aspects of lung cancer clinical trials in the era of targeted agents.

Authors:  Massimo Di Maio; Ciro Gallo; Ermelinda De Maio; Alessandro Morabito; Maria Carmela Piccirillo; Cesare Gridelli; Francesco Perrone
Journal:  Lung Cancer       Date:  2009-10-28       Impact factor: 5.705

Review 3.  The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

Authors:  Josep Tabernero
Journal:  Mol Cancer Res       Date:  2007-03       Impact factor: 5.852

4.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Authors:  Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; Sang-We Kim; Caicun Zhou; Wu-Chou Su; Mengzhao Wang; Yan Sun; Dae Seog Heo; Lucio Crino; Eng-Huat Tan; Tsu-Yi Chao; Mehdi Shahidi; Xiuyu Julie Cong; Robert M Lorence; James Chih-Hsin Yang
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316

5.  Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.

Authors:  James R Tonra; Dhanvanthri S Deevi; Erik Corcoran; Huiling Li; Su Wang; Francine E Carrick; Daniel J Hicklin
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

6.  KIF5B-RET fusions in lung adenocarcinoma.

Authors:  Takashi Kohno; Hitoshi Ichikawa; Yasushi Totoki; Kazuki Yasuda; Masaki Hiramoto; Takao Nammo; Hiromi Sakamoto; Koji Tsuta; Koh Furuta; Yoko Shimada; Reika Iwakawa; Hideaki Ogiwara; Takahiro Oike; Masato Enari; Aaron J Schetter; Hirokazu Okayama; Aage Haugen; Vidar Skaug; Suenori Chiku; Itaru Yamanaka; Yasuhito Arai; Shun-Ichi Watanabe; Ikuo Sekine; Seishi Ogawa; Curtis C Harris; Hitoshi Tsuda; Teruhiko Yoshida; Jun Yokota; Tatsuhiro Shibata
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

7.  Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).

Authors:  Jin Soo Lee; Vera Hirsh; Keunchil Park; Shukui Qin; Cesar R Blajman; Reury-Perng Perng; Yuh-Min Chen; Laura Emerson; Peter Langmuir; Christian Manegold
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

8.  Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

Authors:  Richard H de Boer; Óscar Arrieta; Chih-Hsin Yang; Maya Gottfried; Valorie Chan; Johann Raats; Filippo de Marinis; Raymond P Abratt; Jürgen Wolf; Fiona H Blackhall; Peter Langmuir; Tsveta Milenkova; Jessica Read; Johan F Vansteenkiste
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

9.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Authors:  Roy S Herbst; Yan Sun; Wilfried E E Eberhardt; Paul Germonpré; Nagahiro Saijo; Caicun Zhou; Jie Wang; Longyun Li; Fairooz Kabbinavar; Yukito Ichinose; Shukui Qin; Li Zhang; Bonne Biesma; John V Heymach; Peter Langmuir; Sarah J Kennedy; Hiroomi Tada; Bruce E Johnson
Journal:  Lancet Oncol       Date:  2010-07       Impact factor: 41.316

10.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Authors:  Francesca Carlomagno; Donata Vitagliano; Teresa Guida; Fortunato Ciardiello; Giampaolo Tortora; Giancarlo Vecchio; Anderson J Ryan; Gabriella Fontanini; Alfredo Fusco; Massimo Santoro
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.